Increased circulating TREM2+ microglia extracellular vesicles in aged APP/PS1 Alzheimer's disease rats
Myers, S. J.; Allman, B. L.; Pasternak, S. H.; Whitehead, S. N.; Roseborough, A. D.
Show abstract
INTRODUCTIONTREM2 is a microglial marker important in Alzheimers disease (AD) pathogenesis, but current methods to detect microglial TREM2 expression in vivo are limited. Circulating microglia-derived extracellular vesicles (EVs) show promise as potential biomarkers for AD and may offer insight into TREM2 activity. METHODSTMEM119+/TREM2+ EVs were assessed using nanoscale flow cytometry in plasma from wildtype and APP/PS1 rats aged to 3-, 9-, and 15-months-old. Molecular and histological assays were used to assess microglia markers in rat brain tissue and a radial arm water maze task was employed to evaluate spatial working and reference memory. RESULTSCirculating TMEM119+/TREM2+ EVs were increased in 15-month APP/PS1 rats and associated with severity of cognitive impairment. TREM2 brain expression varied by anatomical region, age, transgene, and assay. DISCUSSIONCollectively, this study provides the first assessment of TMEM119+/TREM2+ EVs as a biomarker of brain microglial expression and cognition in an AD rat model.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A Trem2*R47H mouse model without cryptic splicing drives age- and disease-dependent tissue damage and synaptic loss in response to plaques 96%
- Diabetic phenotype in mouse and humans with β-amyloid pathology reduces the number of microglia around β-amyloid plaques 96%
- APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology 95%
Similar papers in this journal
- Serum metabolome profiling in patients with mild cognitive impairment reveals sex differences in lipid metabolism 95%
- Regional interneuron transcriptional changes reveal pathologic markers of disease progression in a mouse model of Alzheimer's disease 95%
- An interim exploratory biomarker analysis of a Phase 2 clinical trial to assess the impact of CT1812 in Alzheimers disease 94%
Similar papers in this journal
- Microglial SIRT2 deficiency aggravates cognitive decline and amyloid pathology in Alzheimer's disease 97%
- Long-term Nrf2-driven microglial repopulation mitigates microgliosis, neuronal loss and cognitive deficits in tauopathy 96%
- Transcriptomic and functional analysis of Aβ1-42 oligomer-stimulated human monocyte-derived microglia-like cells 94%